Amarin reported $49.22M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 16.99B 1.99B Jun/2026
Alnylam Pharmaceuticals USD 1.29B 120M Jun/2026
Amarin USD 49.22M 451K Dec/2025
AstraZeneca USD 15.38B 90M Jun/2026
BioCryst Pharmaceuticals USD 218.25M 188.3M Jun/2026
DBV Technologies USD 645K 2.13M Dec/2025
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Halozyme Therapeutics USD 481M 104M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Ionis Pharmaceuticals USD 268M 22M Jun/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Neurocrine Biosciences USD 959M 148M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026